Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin

Platelets

Volumn 22, Issue 3, 2011, Pages 179-187

  Crescente, M ^a,c   Mezzasoma, A M ^a   Del Pinto, M ^b   Palmerini, F ^a   Di Castelnuovo, A ^c   Cerletti, C ^c   De Gaetano, G ^c   Gresele, P ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Perugia Hospital   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Aspirin resistance; light transmission aggregometry; platelet function analyzer; recurrent ischemic events; serum TxB2; von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CYCLOOXYGENASE 1; THROMBOXANE A2; THROMBOXANE B2; VON WILLEBRAND FACTOR;

ADULT; ANALYTIC METHOD; ANALYZER; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ERYTHROCYTE COUNT; FEMALE; HEART INFARCTION; HUMAN; LABORATORY TEST; LIGHT TRANSMISSION AGGREGOMETRY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PLATELET FUNCTION ANALYZER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SIGNAL TRANSDUCTION; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

AGED; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

ANGINA;

EID: 79954473617     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.543710     Document Type: Article

References (52)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
2. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373: 1849-1860.
3. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383. (Pubitemid 41713749)
4. Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5:230-237. (Pubitemid 46958838)
5. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008;99:14-26.
6. de Gaetano G, Crescente M, Cerletti C. Current concepts about inhibition of platelet aggregation. Platelets 2008;19:565-570.
7. Harrison P, Keeling D. Laboratory monitoring of antiplatelet therapy. In: Gresele P, Fuster V, Lopez JA, Page CP, Vermylen J, eds. Platelets in Hematologic and Cardiovascular Disorders. A Clinical Handbook. Cambridge University Press 2008: 386-407.
8. Cattaneo M. Laboratory detection of ''aspirin resistance'': What test should we use (if any)? Eur Heart J 2007;28:1702-1708.
9. Patrono C, Rocca B. Aspirin: Promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 2008;28:25-32.
10. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review. Am Heart J 2007;153:175-181. (Pubitemid 46096871)
11. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708. (Pubitemid 47227104)
12. Patrono C. Aspirin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-1713.
13. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-1987. (Pubitemid 39482419)
14. Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008;99:1129-1131. (Pubitemid 351810502)
15. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007;167:1593-1599. (Pubitemid 47280339)
16. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ''resistance'' and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008;36:195-198. (Pubitemid 351212675)
17. Reny JL, de Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A systematic review and meta-analysis. J Thromb Haemost 2008;6:444-450. (Pubitemid 351280111)
18. Frelinger 3rd AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009;120:2586-2596.
19. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study. Thromb Res 2006;118:487-493. (Pubitemid 44292804)
20. Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: Insights into the STRATEGY Study. J Am Coll Cardiol 2006;48:2178-185. (Pubitemid 44873056)
21. Feuring M, Wehling M, Ruf A, Schultz A. Circadian variation of platelet function measured with the PFA-100. Platelets 2009;20:466-470.
22. Gresele P, Catalano M, Giammarresi C, Volpato R, Termini R, Ciabattoni G, et al. Platelet activation markers in patients with peripheral arterial disease-a prospective comparison of different platelet function tests. Thromb Haemost 1997;78:1434-1437. (Pubitemid 27519385)
23. Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica 2007;92:1647-1654. (Pubitemid 350248244)
24. Gouya G, Jilma B, Niel M, Eichelberger B, Wolzt M, Panzer S. Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: A double blind randomized placebo controlled trial. Platelets 2009;20:171-176.
25. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316-321. (Pubitemid 30093238)
26. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008;19:119-124. (Pubitemid 351302375)
27. Corazzi T, Leone M, Maucci R, Corazzi L, Gresele P. Direct and irreversible inhibition of cyclooxygenase-1 (COX-1) by nitroaspirin (NCX 4016). J Pharmacol Exp Ther 2005;315:1331-1337. (Pubitemid 41635422)
28. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235. (Pubitemid 32721947)
29. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115:3156-3164. (Pubitemid 47012230)
30. Leone M, Mezzasoma AM, Davì G, Gresele P. Detection of a critical degree of platelet TxA2-production inhibition by the PFA100 in aspirin-treated subjects: Possible relevance for the monitoring of aspirin resistance. J Thromb Haemost 2005;3:P0964.
31. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319.
32. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37:2153-2158. (Pubitemid 44309919)
33. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin ''resistance''. J Am Coll Cardiol 2009;53:667-677.
34. Pignatelli P, Di Santo S, Barillà F, Gaudio C, Violi F. Multiple anti-atherosclerotic treatments impair aspirin compliance: Effects on aspirin resistance. J Thromb Haemost 2008;6:1832-1834.
35. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705-1709. (Pubitemid 41531626)
36. Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003;102:4594-4599. (Pubitemid 37494129)
37. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-49. (Pubitemid 35284424)
38. Godeneche G, Sorel N, Ragot S, Chomel JC, Neau JP, Macchi L. Stroke and aspirin non-responder patients: Relation with hypertension and platelet response to adenosine diphosphate. Platelets 2009;20:471-477.
39. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186. (Pubitemid 17007095)
40. Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983;61:1081-1085. (Pubitemid 13099894)
41. Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Trifirò E, Di Renzo L, Violi F. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 2005;3:2784-2789. (Pubitemid 41819808)
42. Minuz P, Gaino S, Zuliani V, Tommasoli RM, Benati D, Ortolani R, et al. Functional role of p38 mitogen activated protein kinase in platelet activation induced by a thromboxane A2 analogue and by 8-iso-prostaglandin F2alpha. Thromb Haemost 2002;87:888-898. (Pubitemid 34516619)
43. Minuz P, Fumagalli L, Gaino S, Tommasoli RM, Degan M, Cavallini C, et al. Rapid stimulation of tyrosine phoshorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human platelets. Biochem J 2006;400:127-134. (Pubitemid 44763827)
44. Bach J, Kammerer I, Isgro F, Haubelt H, Vogt A, Saggau W, Hellstern P. The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery. Platelets 2009;20:150-157.
45. Fuchs I, Spiel AO, Frossard M, Derhaschnig U, Riedmü ller E, Jilma B. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. Crit Care Med 2010;38:1423-1429.
46. Brambilla M, Parolari A, Camera M, Colli S, Eligini S, Centenaro C, et al. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost 2010;103:516-524.
47. de Gaetano G, Cerletti C. Platelet function, antiplatelet therapy and clinical outcomes: To test or not to test ?J Thromb Haemost 2007;5:1835-1838. (Pubitemid 47288939)
48. Santos MT, Valles J, Lago A, Tembl J, Sánchez E, Moscardo A, Cosin J. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 2008;6:615-621. (Pubitemid 351404928)
49. Momi S, Falcinelli E, Giannini S, Ruggeri L, Cecchetti L, Corazzi T, et al. Loss of matrix metalloproteinase-2 (MMP-2) in platelets reduces arterial thrombosis in vivo. J Exp Med 2009;206:2365-2379.
50. Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: A potential target or antiplatelet therapy. Trends Pharmacol Sci 2008;29:352-360.
51. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD. Aspirin 'resistance': Role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008;6:2035-2044.
52. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007;115:2490-2496. (Pubitemid 46763222)